Maria Hemming-Harlo1,2, Marja-Leena Lähdeaho2, Markku Mäki3, Timo Vesikari1. 1. From the Vaccine Research Center, Tampere University. 2. Department of Pediatrics, Tampere University Hospital. 3. Tampere Center for Child Health Research, Tampere University and Tampere University Hospital, Tampere, Finland.
Abstract
BACKGROUND: Rotavirus (RV) infection has been proposed to trigger type 1 diabetes mellitus (DM1) and celiac disease (CD) by molecular mimicry in genetically susceptible children. If so, a live attenuated oral RV vaccine could also trigger these autoimmune diseases, or else, prevent the effect of wild-type RV infection. METHODS: In Rotavirus Efficacy and Safety Trial, conducted between 2001 and 2003, the participant children receivedRotaTeq (Kenilworth, NJ) vaccine or placebo in 1:1 ratio. The surveillance was extended as Finnish Extension Study. A questionnaire was sent in 2015 to the parents of 19,133 Finnish Extension Study participants and 5764 (30%) returned the questionnaire. Diagnosis of DM1, biopsy-proven CD and other autoimmune disease over the 11-14 year period were inquired. RESULTS: At the time of questionnaire, the prevalence of DM1 was similar in both groups, 0.97% (25 of 2580 children) in the placebo group and 1.04% (33 of 3184 children) in the vaccine group (P = 0.810). The prevalence of CD was significantly higher in placebo recipients (1.11%; confidence interval: 0.78%-1.6%) than in vaccine recipients (0.60%; confidence interval: 0.38%-0.93%) (P = 0.027). CONCLUSIONS: RV vaccination using RotaTeq did not alter the occurrence of DM1 but decreased the prevalence of CD in childhood and adolescence. We propose that wild-type RV may trigger CD and the triggering effect can be prevented or reduced by RV vaccination.
RCT Entities:
BACKGROUND: Rotavirus (RV) infection has been proposed to trigger type 1 diabetes mellitus (DM1) and celiac disease (CD) by molecular mimicry in genetically susceptible children. If so, a live attenuated oral RV vaccine could also trigger these autoimmune diseases, or else, prevent the effect of wild-type RV infection. METHODS: In Rotavirus Efficacy and Safety Trial, conducted between 2001 and 2003, the participantchildren received RotaTeq (Kenilworth, NJ) vaccine or placebo in 1:1 ratio. The surveillance was extended as Finnish Extension Study. A questionnaire was sent in 2015 to the parents of 19,133 Finnish Extension Study participants and 5764 (30%) returned the questionnaire. Diagnosis of DM1, biopsy-proven CD and other autoimmune disease over the 11-14 year period were inquired. RESULTS: At the time of questionnaire, the prevalence of DM1 was similar in both groups, 0.97% (25 of 2580 children) in the placebo group and 1.04% (33 of 3184 children) in the vaccine group (P = 0.810). The prevalence of CD was significantly higher in placebo recipients (1.11%; confidence interval: 0.78%-1.6%) than in vaccine recipients (0.60%; confidence interval: 0.38%-0.93%) (P = 0.027). CONCLUSIONS: RV vaccination using RotaTeq did not alter the occurrence of DM1 but decreased the prevalence of CD in childhood and adolescence. We propose that wild-type RV may trigger CD and the triggering effect can be prevented or reduced by RV vaccination.
Authors: Rachel M Burke; Jacqueline E Tate; Rebecca M Dahl; Sharon Saydah; Giuseppina Imperatore; Edward W Gregg; Umesh D Parashar Journal: JAMA Pediatr Date: 2020-04-01 Impact factor: 16.193
Authors: Katri Lindfors; Jake Lin; Hye-Seung Lee; Heikki Hyöty; Matti Nykter; Kalle Kurppa; Edwin Liu; Sibylle Koletzko; Marian Rewers; William Hagopian; Jorma Toppari; Annette-Gabriele Ziegler; Beena Akolkar; Jeffrey P Krischer; Joseph F Petrosino; Richard E Lloyd; Daniel Agardh Journal: Gut Date: 2019-11-19 Impact factor: 31.793
Authors: Birgit Rami-Merhar; Sabine E Hofer; Elke Fröhlich-Reiterer; Thomas Waldhoer; Maria Fritsch Journal: Pediatr Diabetes Date: 2020-05-31 Impact factor: 4.866